Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 628 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR News digest – sponge on a string, junk food watershed, prostate... August 1, 2020 FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer... October 16, 2023 “Your Stories” Podcast: Amplifying Patient Voices September 8, 2020 Tables Turned June 23, 2020 Load more HOT NEWS Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive... FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... How Becky is helping her children to keep their dad’s memory... American Cancer Society Report Shows Economic, Racial Disparities in Cancer Outcomes
